Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Prof Paresh Vyas is leading a new clincal trial at Oxford's Churchill Hospital which plans to study the safety of a new experimental drug to treat a form of leukaemia, called Acute Myeloid Leukaemia (AML).

Credit: Katja Gehmlich and Charlotte Hooper

From the RDM Image Competition 2015. 

The cells shown here are COS-1 cells. This is a monkey fibroblast cell line, which we use in the lab to produce recombinant proteins in a cellular environment, e.g. to compare disease-causing mutants with their wild-type counterparts. In this particular image, the actin cytoskeleton of the cells is stain in red (using phalloidin, a toxin of the death cap mushroom) and their nuclei are stained in green (using DAPI, 4',6-diamidino-2-phenylindole, a substance that binds to DNA).
Load More